Odyssey Thera, Inc. Announces New Equity Financing and Initiation of Research
Contract with Merck
SAN RAMON, Calif., Feb. 14, 2013
SAN RAMON, Calif., Feb. 14, 2013 /PRNewswire/ --Odyssey Thera, Inc., a
privately held biotechnology company, announced today a new equity financing
and the initiation of a research service contract with Merck, known as MSD
outside the U.S. and Canada.
Additional participants in this financing include HBM Partners, Burrill &
Company, and Lonza. The financing, comprising new funds and debt conversion,
totals $2.8M. These funds will be used to support continued advancement and
expanded commercialization of Odyssey Thera's technologies and products.
"The support from current and new investors will expedite commercialization of
Odyssey Thera technologies," said Dr. John K. Westwick, President and CEO of
Odyssey Thera. "We look forward to supporting Merck and other leading
discovery and development programs with these validated capabilities."
About Odyssey Thera, Inc.
Odyssey Thera was founded over ten years ago with the goal of transforming
drug discovery through deep cellular analysis. Odyssey's patented technologies
measure disease-relevant pathway activity within living human cells.
Unprecedented throughput and breadth of high-content assays enables assessment
of key signaling nodes as well as the cellular system, allowing for rapid
identification of drug candidates with optimal efficacy and safety profiles.
The Company's leadership position in fundamental patents, technology, and
know-how relating to cellular analysis has led to alliances with Pfizer,
Abbott, Merck, the U.S. EPA, and others. To learn more about Odyssey Thera,
please visit www.odysseythera.com.
SOURCE Odyssey Thera, Inc.
Contact: John Westwick, +1-925-242-5011, jwestwick@OdysseyThera.com
Press spacebar to pause and continue. Press esc to stop.